A Phase 3 interventional study of CAZ-AVI and Metronidazole in Complicated Intra-Abdominal Infection, sponsored by Pfizer. Completed at 57 sites in 20 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-09-06.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Intraabdominal Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Intraabdominal Infections · Pfizer.
Among the 19 studies in Intraabdominal Infections by Pfizer, this one has the largest enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2012, is one of 5 in phase 3, and was the 10th registered.
129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.
Browse Intraabdominal Infections studies →None of the 19 studies in Intraabdominal Infections by Pfizer is open now. The open studies under Intraabdominal Infections, anywhere →
Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 493 is above the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.
Median enrollment 144 across the 14 interventional studies, 203 across the 5 observational. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Intraabdominal Infections by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patient is authorized to participate if at least one of the following criteria are met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV treatment
Drug: CAZ-AVI · Drug: Metronidazole
IV treatment
Drug: Meropenem
Ceftazidime 2000 mg and 500 mg of avibactam
500 mg of Metronidazole
1 gram of Meropenem
Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA).
The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention is necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, death where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. Results from two identical protocols D4280C00001 and D4280C00005 combined into a single database with agreement from FDA and EMA.
Time frame: TOC: 28 to 35 days after start of study drug
Clinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set (Co-primary Outcome for Rest of World [ROW]).
The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure.
Time frame: TOC: 28 to 35 days after start of study drug
Clinical Response at the TOC Visit in the Clinically Evaulable (CE) Analysis Set (Co-primary Outcome for Rest of World [ROW]).
The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: TOC: 28 to 35 days after start of study drug
Clinical Cure at TOC in the Microbiologically Evaluable Analysis Set
The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: TOC: 28 to 35 days after start of study drug
Clinical Cure at TOC in the Extended Microbiologically Evaluable Analysis Set
The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: TOC: 28 to 35 days after start of study drug
Clinical Response by Visit in the Primary Population: Microbiologically Modified Intent-to-Treat (mMITT)
Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure.
Time frame: EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU: 42 to 49 days after start of study drug
Per-patient Microbiological Response in the Microbiologically Modified Intent- To-Treat Analysis Set
Microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to a surgical review panel (SRP) assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).
Time frame: EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU 42 to 49 days after start of study drug
Per-pathogen Microbiological Response at TOC in the Microbiologically Modified Intent-To-Treat Analysis Set.
The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: TOC: 28 to 35 days after start of study drug.
Clinical Response by Pathogen at TOC for Patients Infected With Ceftazidime-resistant Pathogens in Microbiological Modified Intent to Treat Analysis Set
Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: Test of Cure: 28 to 35 days after start of study drug
Favorable Per-pathogen Microbiological Response for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set
The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: TOC: 28 to 35 days after start of study drug
Per-patient Microbiological Response at TOC for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set
Microbiological responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).
Time frame: Test of Cure: 28 to 35 days after start of study drug
Number of Patients Afebrile at Last Observation in the Clinically Evaluable Analysis Set for Patients Who Have Fever at Study Entry
Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day.
Time frame: Test of Cure: 1 to 14 days after start of study drug
Plasma Concentrations for Ceftazidime and Avibactam
Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations
Time frame: Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug
Results from two identical protocols D4280C00001 and D4280C00005 combined into a single database with agreement from FDA and EMA. First patient enrolled 22 March 2012 and last patient's last visit was 07 April 2014. Patients were adults hospitalised with complicated intra-abdominal infection (cIAI) that required surgery and IV antibiotics.
| Milestone | CAZ-AVI + Metronidazole | Meropenem |
|---|---|---|
| Started | 529 | 529 |
| Completed | 474 | 494 |
| Not completed | 55 | 35 |
| Withdrew: Withdrawal by subject | 22 | 15 |
| Withdrew: Not specified in study report | 11 | 5 |
| Withdrew: Condition improved/subject recovered | 1 | 0 |
| Withdrew: Lack of efficacy | 7 | 8 |
| Withdrew: Adverse event | 14 | 7 |
The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention is necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, death where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. Results from two identical protocols D4280C00001 and D4280C00005 combined into a single database with agreement from FDA and EMA.
| Participants | CAZ-AVI + Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 337 | 349 |
| Clinical failure | 37 | 30 |
| Indeterminate | 39 | 31 |
The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure.
| Participants | CAZ-AVI + Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 429 | 444 |
| Clinical failure | 47 | 39 |
| Indeterminate | 44 | 40 |
The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Participants | CAZ-AVI + Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 376 | 385 |
| Clinical failure | 34 | 31 |
The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Participants | CAZ-AVI + Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 244 | 272 |
| Clinical failure | 21 | 15 |
The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Participants | CAZ-AVI + Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 248 | 278 |
| Clinical failure | 22 | 16 |
Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure.
| Participants | CAZ-AVI + Metronidazole (EOT) | Meropenem (EOT) | CAZ-AVI + Metronidazole (TOC) | Meropenem (TOC) | CAZ-AVI + Metronidazole (LFU) | Meropenem (LFU) |
|---|---|---|---|---|---|---|
| Clinical cure | 361 | 379 | 337 | 349 | 340 | 347 |
| Clinical failure | 30 | 19 | 37 | 30 | 38 | 31 |
| Indeterminate | 22 | 12 | 39 | 31 | 35 | 32 |
Microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to a surgical review panel (SRP) assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).
| Participants | CAZ-AVI + Metronidazole (EOT) | Meropenem (EOT) | CAZ-AVI + Metronidazole (TOC) | Meropenem (TOC) | CAZ-AVI + Metronidazole (LFU) | Meropenem (LFU) |
|---|---|---|---|---|---|---|
| Favourable response | 362 | 379 | 337 | 349 | 340 | 347 |
| Unfavourable response | 30 | 19 | 37 | 31 | 38 | 32 |
| Indeterminate | 21 | 12 | 39 | 30 | 35 | 31 |
The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants | CAZ-AVI + Metronidazole | Meropenem | CAZ-AVI + Metronidazole (Denominator) | Meropenem (Denominator) |
|---|---|---|---|---|
| Citrobacter freundii complex | 14 | 9 | 18 | 12 |
| Enterobacter aerogenes | 4 | 5 | 5 | 5 |
| Enterobacter cloacae | 11 | 16 | 13 | 19 |
| Escherichia coli | 218 | 249 | 271 | 285 |
| Klebsiella oxytoca | 14 | 12 | 18 | 15 |
| Klebsiella pneumoniae | 40 | 37 | 51 | 49 |
| Proteus mirabilis | 5 | 7 | 8 | 9 |
| Pseudomonas aeruginosa | 30 | 34 | 35 | 36 |
| Enterococcus avium | 8 | 10 | 8 | 15 |
| Enterococcus faecalis | 22 | 23 | 31 | 28 |
| Enterococcus faecium | 13 | 18 | 16 | 22 |
| Staphylococcus aureus | 17 | 14 | 18 | 14 |
| Streptococcus anginosus group | 59 | 50 | 72 | 61 |
| Streptococcus bovis group | 2 | 6 | 3 | 7 |
| Streptococcus mitis group | 10 | 9 | 15 | 11 |
| Bacteroides fragilis | 45 | 38 | 52 | 47 |
| Bacteroides ovatus | 17 | 17 | 22 | 20 |
| Bacteroides stercoris | 9 | 1 | 10 | 1 |
| Bacteroides thetaiotaomicron | 18 | 21 | 22 | 25 |
| Bacteroides uniformis | 4 | 6 | 7 | 7 |
| Bacteroides vulgatus | 6 | 6 | 8 | 9 |
| Clostridium perfringens | 7 | 4 | 10 | 4 |
| Eggerthella lenta | 5 | 7 | 5 | 8 |
| Parabacteroides distasonis | 13 | 12 | 16 | 13 |
| Parvimonas micra | 7 | 8 | 7 | 10 |
Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Participants | CAZ-AVI + Metronidazole | Meropenem | CAZ-AVI + Metronidazole (Denominator) | Meropenem (Denominator) |
|---|---|---|---|---|
| All | 39 | 55 | 47 | 64 |
| Citrobacter freundii complex | 1 | 2 | 1 | 2 |
| Enterobacter aerogenes | 0 | 1 | 0 | 1 |
| Enterobacter cloacae | 2 | 7 | 3 | 7 |
| Escherichia coli | 19 | 31 | 24 | 37 |
| Klebsiella pneumoniae | 10 | 9 | 13 | 13 |
| Morganella morganii | 1 | 1 | 2 | 1 |
| Proteus mirabilis | 2 | 3 | 2 | 3 |
| Serratia marcescens | 1 | 0 | 1 | 0 |
| Alcaligenes faecalis | 1 | 2 | 1 | 2 |
| Comamonas testosteroni | 1 | 0 | 1 | 0 |
| Pseudomonas aeruginosa | 2 | 4 | 2 | 4 |
The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants | CAZ-AVI + Metronidazole | Meropenem | CAZ-AVI + Metronidazole (Denominator) | Meropenem (Denominator) |
|---|---|---|---|---|
| Citrobacter freundii complex | 1 | 2 | 2 | 2 |
| Enterobacter aerogenes | 0 | 1 | 0 | 1 |
| Enterobacter cloacae | 2 | 7 | 3 | 7 |
| Escherichia coli | 19 | 31 | 24 | 37 |
| Klebsiella pneumoniae | 10 | 9 | 13 | 13 |
| Morganella morganii | 1 | 1 | 2 | 1 |
| Proteus mirabilis | 2 | 3 | 2 | 3 |
| Serratia marcescens | 1 | 0 | 1 | 0 |
| Alcaligenes faecalis | 1 | 2 | 1 | 2 |
| Comamonas testosteroni | 1 | 0 | 1 | 0 |
| Pseudomonas aeruginosa | 2 | 4 | 2 | 4 |
Microbiological responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).
| Participants | CAZ-AVI + Metronidazole | Meropenem |
|---|---|---|
| Favourable | 39 | 55 |
| Unfavourable | 7 | 1 |
| indeterminate | 2 | 8 |
Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day.
| Participants | CAZ-AVI + Metronidazole | Meropenem |
|---|---|---|
| Number of Patients Afebrile at Last Observation in the Clinically Evaluable Analysis Set for Patients Who Have Fever at Study Entry | 84 | 72 |
Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations
| (NG/ML) | CAZ (1) | AVI (1) | CAZ (2) | AVI (2) | CAZ (3) | AVI (3) |
|---|---|---|---|---|---|---|
| Plasma Concentrations for Ceftazidime and Avibactam | 50823.0 (171 to 3110000) | 9229.4 (13 to 693000) | 40053.1 (155 to 235000) | 7163.9 (15 to 46800) | 10967.6 (159 to 151000) | 1690.7 (14 to 30800) |
Collected over Adverse event data were collected from the screening/consent visit until the late follow-up visit (ie Day -1/0 to Day 42).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CAZ-AVI + Metronidazole | — | 17/529 (3.2%) | 184/529 (34.8%) |
| Meropenem | — | 15/529 (2.8%) | 152/529 (28.7%) |
| Event | CAZ-AVI + Metronidazole | Meropenem |
|---|---|---|
| Renal failure acuteRenal and urinary disorders | 5/529 | 0/529 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/529 | 3/529 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/529 | 1/529 |
| Myocardial infarctionCardiac disorders | 1/529 | 2/529 |
| Transaminases increasedInvestigations | 0/529 | 2/529 |
| Gastrointestinal stoma necrosisInjury, poisoning and procedural complications | 2/529 | 0/529 |
| Abdominal abscessInfections and infestations | 0/529 | 2/529 |
| BronchopneumoniaInfections and infestations | 2/529 | 2/529 |
| Candida sepsisInfections and infestations | 2/529 | 0/529 |
| Cardiac failureCardiac disorders | 2/529 | 1/529 |
| Event | CAZ-AVI + Metronidazole | Meropenem |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 40/529 | 17/529 |
| NauseaGastrointestinal disorders | 36/529 | 24/529 |
| HypertensionVascular disorders | 15/529 | 24/529 |
| VomitingGastrointestinal disorders | 24/529 | 10/529 |
| PyrexiaGeneral disorders | 24/529 | 24/529 |
| ConstipationGastrointestinal disorders | 8/529 | 20/529 |
| HeadacheNervous system disorders | 15/529 | 9/529 |
| Wound infectionInfections and infestations | 13/529 | 11/529 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/529 | 13/529 |
| HypotensionVascular disorders | 12/529 | 12/529 |
The MITT analysis set includes all patients who met the disease definition for cIAI and received at least 1 dose of study drug. 15 patients excluded received at least one dose of study drug but failed the minimum disease criteria.
| Age, Continuous(Years) | CAZ-AVI + Metronidazole | Meropenem | Total |
|---|---|---|---|
| Mean | 49.8 ± 17.48 | 50.3 ± 18.29 | 50.0 ± 17.88 |
| Sex: Female, Male(Participants) | CAZ-AVI + Metronidazole | Meropenem | Total |
|---|---|---|---|
| Female | 194 | 191 | 385 |
| Male | 326 | 332 | 658 |
The record gives a start of Mar 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole